Recently, Eltrombopag, an FDA-approved drug for immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, emerged as a potential HuR inhibitor. The gene discussed is ELAVL1; the disease is autoimmune thrombocytopenic purpura.